Does Tricare Cover Wegovy? Insurance Guide 2026

Weight management and metabolic health are critical components of overall well-being, particularly for military personnel and their families. As obesity and type 2 diabetes rates continue to rise, medications like Wegovy have emerged as powerful tools to support long-term health. But does Tricare, the healthcare program serving uniformed service members, retirees, and their dependents, cover Wegovy? This comprehensive guide explores Tricare’s coverage policies for Wegovy in 2026, including eligibility, costs, and steps to secure approval.

Does Tricare Cover Wegovy for Diabetes?

Tricare’s coverage of Wegovy for diabetes management depends on clinical necessity and alignment with FDA-approved indications. Wegovy, a brand name for semaglutide, is FDA-approved for chronic weight management but is also recognized for its benefits in improving glycemic control in individuals with type 2 diabetes. While Tricare does not explicitly list Wegovy as a covered medication for diabetes, it may approve it under specific circumstances if prescribed off-label for patients with comorbid obesity and diabetes.

To qualify, providers must demonstrate that Wegovy is medically necessary to achieve better blood sugar control when other diabetes medications (e.g., metformin, insulin) have failed or caused intolerable side effects. Tricare typically requires prior authorization, and approval is more likely if the patient has a BMI ≥ 27 with weight-related complications, such as hypertension or dyslipidemia. Additionally, documentation must show that Wegovy is part of a broader treatment plan, including diet, exercise, and behavioral therapy.

If Wegovy is denied for diabetes, patients can appeal with additional evidence, such as HbA1c levels or records of failed alternative treatments. While Tricare’s formulary prioritizes diabetes-specific medications like Ozempic (another semaglutide), Wegovy may still be accessible with strong clinical justification.

Does Tricare Cover Wegovy for Weight Loss?

Tricare’s coverage of Wegovy for weight loss is contingent on strict clinical criteria. Wegovy is FDA-approved for chronic weight management in adults with a BMI ≥ 30 or a BMI ≥ 27 with at least one weight-related condition (e.g., hypertension, sleep apnea). Tricare generally aligns with these guidelines but requires prior authorization to ensure medical necessity.

To qualify, patients must have documented evidence of failed weight loss attempts through lifestyle modifications (e.g., diet, exercise) for at least six months. Tricare also mandates that Wegovy be prescribed as part of a comprehensive weight management program, including nutritional counseling and physical activity plans. Providers must submit detailed records, such as BMI history, weight-related comorbidities, and prior treatment efforts, to support the request.

If approved, Tricare typically covers Wegovy for up to 12 months, with the possibility of renewal if the patient demonstrates significant weight loss (e.g., ≥ 5% of body weight). However, coverage may be denied if the patient has a history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, as Wegovy carries a black-box warning for these conditions. Patients denied coverage can appeal with additional clinical evidence or letters of medical necessity from their provider.

How Much Does Wegovy Cost With Tricare?

The out-of-pocket cost of Wegovy with Tricare varies based on the beneficiary’s plan, pharmacy network, and whether the medication is obtained through a military treatment facility (MTF) or a retail pharmacy. As of 2026, Wegovy is classified as a Tier 3 (non-preferred brand) medication on Tricare’s formulary, meaning it is not fully covered without prior authorization.

For active-duty service members, Wegovy may be available at no cost if dispensed through an MTF, provided the MTF has the medication in stock. However, MTFs often have limited supplies, and patients may need to use retail pharmacies. At retail pharmacies, Tricare beneficiaries typically pay a copayment of $24 for a 30-day supply (or $60 for a 90-day supply) after meeting their annual deductible. Retirees and dependents under Tricare Prime or Select may face higher copays, ranging from $24 to $60 per month, depending on their plan and pharmacy choice.

Without Tricare coverage, Wegovy can cost $1,300–$1,600 per month, making insurance coverage critical for affordability. Patients can reduce costs by using Tricare’s mail-order pharmacy (Express Scripts), which often offers lower copays for 90-day supplies. Additionally, Novo Nordisk, the manufacturer of Wegovy, offers a savings card that may reduce out-of-pocket costs to $0–$25 per month for eligible patients, though this program may not stack with Tricare benefits.

Wegovy Prior Authorization for Tricare

Obtaining prior authorization for Wegovy through Tricare requires a detailed submission from the prescribing provider, demonstrating that the medication is medically necessary and meets Tricare’s coverage criteria. The prior authorization process ensures that Wegovy is used appropriately and cost-effectively, particularly given its high price and potential for off-label use.

To initiate prior authorization, the provider must submit a Tricare Prior Authorization Request Form (DD Form 2642) along with supporting clinical documentation. This documentation should include:

The patient’s BMI and weight history, including failed weight loss attempts.
Evidence of weight-related comorbidities (e.g., hypertension, type 2 diabetes, sleep apnea).
A detailed treatment plan outlining how Wegovy will be integrated with lifestyle modifications.
Records of prior medications or interventions attempted (e.g., phentermine, bupropion/naltrexone).

Tricare’s Pharmacy Benefits Program reviews the request, typically within 7–10 business days, though urgent cases may be expedited. Approval is more likely if the patient meets the FDA’s criteria for Wegovy (BMI ≥ 30 or BMI ≥ 27 with comorbidities) and has exhausted other weight loss options. If denied, the provider and patient will receive a written explanation, which can be used to guide an appeal.

How to Get Tricare to Cover Wegovy

Securing Tricare coverage for Wegovy requires a strategic approach, combining clinical evidence, provider advocacy, and persistence. Here’s a step-by-step guide to improving your chances of approval:

Consult a Tricare-Affiliated Provider: Work with a primary care physician, endocrinologist, or obesity medicine specialist who is familiar with Tricare’s prior authorization process. Providers within the Tricare network are more likely to understand the documentation requirements and can streamline the submission.
Document Medical Necessity: Ensure your medical records include:
- A BMI ≥ 30 or BMI ≥ 27 with weight-related conditions.
- A history of failed weight loss attempts (e.g., diet, exercise, other medications).
- Evidence of comorbidities (e.g., lab results, sleep study reports, blood pressure logs).
Submit a Comprehensive Prior Authorization Request: Your provider should complete Tricare’s DD Form 2642 and include a letter of medical necessity. The letter should emphasize how Wegovy will improve your health outcomes and reduce long-term healthcare costs (e.g., by preventing diabetes or cardiovascular disease).
Follow Up: After submission, follow up with Tricare’s Pharmacy Benefits Program to confirm receipt and check the status of your request. If additional information is needed, provide it promptly to avoid delays.
Appeal if Denied: If Tricare denies coverage, request a copy of the denial letter and work with your provider to submit an appeal. Include any missing documentation or new evidence, such as updated lab results or a revised treatment plan.
Explore Alternative Coverage Options: If Tricare denies Wegovy, consider using Novo Nordisk’s savings program or switching to a Tricare-approved alternative (e.g., phentermine, Qsymia).

What to Do If Tricare Denies Wegovy

If Tricare denies coverage for Wegovy, don’t lose hope—there are several steps you can take to challenge the decision and potentially secure approval. The first step is to request a copy of the denial letter, which will outline the specific reasons for the rejection. Common reasons for denial include insufficient documentation, failure to meet BMI criteria, or lack of evidence for prior weight loss attempts.

Once you understand the reason for denial, work with your provider to gather additional evidence. For example:

If denied for not meeting BMI criteria, provide updated measurements or documentation of weight-related comorbidities.
If denied for lack of prior weight loss attempts, submit records of diet programs, exercise regimens, or previous medications tried.
If denied due to missing documentation, ensure all required forms (e.g., DD Form 2642) are fully completed and resubmit.

Next, submit a formal appeal through Tricare’s appeals process. Appeals must be filed within 90 days of the denial and should include:

A letter from your provider explaining why Wegovy is medically necessary.
Any new or corrected documentation supporting your case.
A personal statement (if applicable) describing how Wegovy would improve your health and quality of life.

Tricare reviews appeals within 30–60 days, and decisions are typically final. However, if the appeal is denied, you may have the option to request an independent external review through the Department of Defense’s Office of Hearings and Appeals. This process is more formal and may require legal assistance, but it can be effective for complex cases.

Tricare Alternatives If Wegovy Is Not Covered

If Tricare denies coverage for Wegovy, several alternatives may be available, depending on your health goals and insurance coverage. While Wegovy is highly effective for weight loss and metabolic health, other medications and interventions can provide similar benefits.

Tricare-Covered Weight Loss Medications:
- Phentermine: A stimulant-based appetite suppressant approved for short-term weight loss. Tricare covers it with prior authorization for patients with a BMI ≥ 30 or BMI ≥ 27 with comorbidities.
- Qsymia (phentermine/topiramate): A combination medication that suppresses appetite and increases satiety. Tricare may cover it if Wegovy is denied, though it also requires prior authorization.
- Contrave (bupropion/naltrexone): Another combination medication that targets brain pathways involved in hunger and cravings. Tricare coverage varies, so check with your provider.
Lifestyle Interventions:
- Tricare’s Weight Management Programs: Tricare covers nutritional counseling and weight management programs through military treatment facilities or civilian providers. Programs like the MOVE! Weight Management Program (for veterans) or Tricare’s Wellness Programs can provide structured support.
- Bariatric Surgery: For patients with severe obesity (BMI ≥ 40 or BMI ≥ 35 with comorbidities), Tricare covers bariatric surgery (e.g., gastric bypass, sleeve gastrectomy) with prior authorization.
Manufacturer Savings Programs:
- Novo Nordisk offers a savings card for Wegovy, which may reduce out-of-pocket costs to $0–$25 per month for eligible patients. While this program cannot be combined with Tricare, it may be an option if you’re willing to pay out-of-pocket.
Clinical Trials:
- Participating in a clinical trial for weight loss medications may provide access to Wegovy or similar drugs at no cost. Websites like ClinicalTrials.gov list ongoing studies, and some may accept Tricare beneficiaries.

Frequently Asked Questions

Does Tricare cover Wegovy for weight loss?

Tricare may cover Wegovy for weight loss if the patient meets specific criteria, including a BMI ≥ 30 or BMI ≥ 27 with weight-related comorbidities, and has documented failed weight loss attempts. Prior authorization is required, and coverage is typically approved for up to 12 months if the patient demonstrates progress. However, Tricare does not guarantee coverage, and denials are possible if documentation is insufficient.

How much is the Wegovy copay with Tricare?

The copay for Wegovy with Tricare depends on the beneficiary’s plan and pharmacy. Active-duty service members may receive Wegovy at no cost through military treatment facilities, while retirees and dependents typically pay $24 for a 30-day supply or $60 for a 90-day supply at retail pharmacies. Using Tricare’s mail-order pharmacy (Express Scripts) can reduce costs further. Without coverage, Wegovy costs $1,300–$1,600 per month.

Can I appeal if Tricare denies Wegovy?

Yes, you can appeal a Tricare denial for Wegovy by submitting a formal appeal within 90 days of the denial. The appeal should include additional clinical evidence, a letter of medical necessity from your provider, and any corrected documentation. If the appeal is denied, you may request an independent external review through the Department of Defense. Persistence and thorough documentation are key to a successful appeal.